These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26798658)

  • 1. Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
    Wan H; Zhao D; Shen J; Lu L; Zhang T; Chen Z
    J Diabetes Res; 2016; 2016():9849328. PubMed ID: 26798658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes.
    Yuan G; Jia J; Zhang C; Yu S; Dong S; Ye J; Zhu T; Tang B; Qian W; Wang D; Yang L; Zhou L; Mao C
    Endocr J; 2014; 61(5):513-21. PubMed ID: 24621778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections.
    Li FF; Fu LY; Zhang WL; Su XF; Wu JD; Sun J; Ye L; Ma JH
    J Diabetes Res; 2016; 2016():1028945. PubMed ID: 26839889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of β-cell function ameliorated glycemic variability in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion or in combination with sitagliptin treatment: a randomized control trial.
    Yuan G; Hu H; Wang S; Yang Q; Yu S; Sun W; Qian W; Mao C; Zhou L; Chen D; Wang Z; Gong Q; Wang D
    Endocr J; 2015; 62(9):817-34. PubMed ID: 26194272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment.
    Zeng L; Lu H; Deng H; Mu P; Li X; Wang M
    Diabetes Technol Ther; 2012 Jan; 14(1):35-42. PubMed ID: 21877913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
    J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system.
    Li LQ; Yao MY; Ma JX; Xue P; Li YK
    Endocr J; 2019 Oct; 66(10):871-880. PubMed ID: 31243192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
    Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
    Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Islet Transplantation Provides Superior Glycemic Control With Less Hypoglycemia Compared With Continuous Subcutaneous Insulin Infusion or Multiple Daily Insulin Injections.
    Holmes-Walker DJ; Gunton JE; Hawthorne W; Payk M; Anderson P; Donath S; Loudovaris T; Ward GM; Kay TW; OʼConnell PJ
    Transplantation; 2017 Jun; 101(6):1268-1275. PubMed ID: 27490410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S; Sothiratnam R; Sari R; Andersen H; Hiort LC; Rao P
    Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influencing factors for the curative effects of short-term continuous subcutaneous insulin infusion on newly diagnosed type 2 diabetes].
    Li YB; Zhu HL; Yao B; Huang ZM; Ou XZ; Xiao YB; Weng JP
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(9):602-5. PubMed ID: 15949356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.
    Li FF; Jiang LL; Yan RN; Zhu HH; Zhou PH; Zhang DF; Su XF; Wu JD; Ye L; Ma JH
    Medicine (Baltimore); 2016 Oct; 95(43):e5229. PubMed ID: 27787387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
    Mori Y; Taniguchi Y; Miyazaki S; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2013 Mar; 15(3):237-40. PubMed ID: 23402316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
    Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W
    Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
    Huang Z; Wan X; Liu J; Deng W; Chen A; Liu L; Liu J; Wei G; Li H; Fang D; Li Y
    Diabetes Technol Ther; 2013 Oct; 15(10):859-69. PubMed ID: 23991629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous insulin infusion and multiple dose of insulin regimen display similar patterns of blood glucose excursions in pediatric type 1 diabetes.
    Alemzadeh R; Palma-Sisto P; Parton EA; Holzum MK
    Diabetes Technol Ther; 2005 Aug; 7(4):587-96. PubMed ID: 16120030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Body Fat Percentage with Time in Range Generated by Continuous Glucose Monitoring during Continuous Subcutaneous Insulin Infusion Therapy in Type 2 Diabetes.
    Ruan Y; Zhong J; Chen R; Zhang Z; Liu D; Sun J; Chen H
    J Diabetes Res; 2021; 2021():5551216. PubMed ID: 34136580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.
    Ji L; Han P; Wang X; Liu J; Zheng S; Jou YM; O'Neill EA; Golm GT; Engel SS; Kaufman KD; Shankar RR
    J Diabetes Investig; 2016 Sep; 7(5):727-36. PubMed ID: 27181998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.